The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

Completed

• Conditions: Acute Myeloid Leukemia (AML); Ewing Sarcoma

• Registration Number: NCT06659224
• Lead Sponsor: asmaa salama ibrahim

Brief Summary

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-01-01
• Primary Completion: 2021-12-30
• Study Completion: 2021-12-30
• Study First Submitted: 2024-10-23
• Study First Submitted QC: 2024-10-23
• Study First Posted: 2024-10-26
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-18
• Last Update Posted: 2025-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2631

Inclusion Criteria

• Patients diagnosed with Ewing sarcoma
• Latency exclusion period of 6 months
• Sequence 0 or 1

Exclusion Criteria

• patients lacking age documentation or age reported only on death certificates or autopsies

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The standardized incidence ratio and excess risk of developing acute myeloid leukemia in Ewing's sarcoma patients	from Jan, 2000 till Dec, 2021	The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess absolute risk for acute myeloid leukemia in Ewing's sarcoma patients.

Secondary Outcome Measures

Name	Time	Method
The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients across different racial groups	from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients between different stages	from Jan, 2000 till Dec, 2021

Trial Locations

Locations (1)

Suez Canal University; 🇪🇬 Ismailia, Egypt